Veterans & MS

Ricks, Thomas
October 2008
PN;Oct2008, Vol. 62 Issue 10, p81
Trade Publication
The article focuses on the Multiple Sclerosis (MS) and the function of the veterans at the Spinal Cord Injury Center (SCI), for treating MS patients. A SCI unit neurologist said that MS is a neurological disorder which is difficult to treat due to its unknown genetic compositions. An overview of the symptoms of MS is offered. Meanwhile, the SCI centers extend their programs in giving assistance to patients whose conditions are not in severe and in active relapse.


Related Articles

  • Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-Ia in relapsing�remitting multiple sclerosis: a categorical disability trend analysis. Liu, C; Blumhardt, L D // Multiple Sclerosis (13524585);Feb2002, Vol. 8 Issue 1, p10 

    The treatment effects of recent immunomodulatory therapies on disease progression in relapsing-remitting multiple sclerosis (MS) have been mostly established from 'confirmed progression' endpoints. However, the reliability of this outcome measure is poor and a significant proportion of patients...

  • Cost of managing an episode of relapse in multiple sclerosis in the United States. O'Brien, Judith A.; Ward, Alexandra J.; Patrick, Amanda R.; Caro, Jaime // BMC Health Services Research;2003, Vol. 3, p17 

    Background: The purpose of this study was to determine the direct medical US cost of managing multiple sclerosis relapses. Methods: Direct data analysis and cost modeling were employed to derive typical resource use profiles and costs in 2002 US dollars, from the perspective of a third-party...

  • Treatment & Research.  // PN;Nov2008, Vol. 62 Issue 11, p21 

    Information about the World Congress on Treatment and Research in Multiple Sclerosis from September 17-20, 2008 in Montreal, Quebec is presented. Topics include the use of sustained-release Fampridine therapy to people with all types of MS and a report on a sanctioned therapy which may...

  • Collaboration, rapid sourcing among key principles for VA acquisition program. Giddens, Greg // Vantage Point;Aug2016, p13 

    The article reports that Veteran Affairs (VA) is the largest health care system in the U.S. which serves the more than 8 million Veterans enrolled in VA health care.

  • Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Liu, C; Blumhardt, L D // Multiple Sclerosis (13524585);Feb99, Vol. 5 Issue 1, p22 

    Published Phase III immunomodulatory treatment trials in relapsing and remitting multiple sclerosis have demonstrated a modest decline in attack rates, but only a minor effect on disability. As genuine disability progression is difficult to ascertain in relatively short studies with the...

  • Untitled.  // Inside MS;Jan2005, Vol. 23 Issue 1, p13 

    Introduces a series of articles on distinguishing progressive multiple sclerosis from the relapsing forms.

  • Relapses and Progression of Disability in Multiple Sclerosis. Verbanets, Judith A. // Physical Therapy;Jul2001, Vol. 81 Issue 7, p1359 

    Discusses research being done on multiple sclerosis. Reference to study by C. Confavreux and colleagues, published in the 2000 issue of the `Northern England Journal of Medicine'; Physiological manifestations of the progression of multiple sclerosis; Relapses of disability.

  • LONG-TERM ECONOMIC IMPLICATIONS OF REDUCED RATES OF RELAPSE.  // Managed Healthcare Executive;Aug2004 Supplement, Vol. 14, p8 

    Focuses on the long-term economic implications of multiple sclerosis management in the U.S. Prevention of relapse and its associated burden disability; Reduction in hospitalization; Decline in the rates of healthcare resource utilization.

  • Teriflunomide Associated With Reductions in Severe MS Relapses. Summers, Jaye // MD Conference Express;May2015, Vol. 15 Issue 9, p17 

    The TEMSO and TOWER trials demonstrate that both doses of teriflunomide (7 mg and 14 mg) each significantly reduce the annualized relapse rates in patients with relapsing multiple sclerosis. Post hoc analyses of both trials indicate that only teriflunomide 14 mg significantly reduces the rate of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics